日报更新时间：
周报更新时间：06-25 22:35
今开价：38.4
最高价：39.8
成交量：3694435.0
昨收价：37.96
最低价：35.916
最新价：36.49
英文名称：Axsome Therapeutics
简介：Axsome Therapeutics, Inc.成立于2012年1月
电话：1-212-3323241
Axsome Therapeutics, Inc.是一家临床阶段的生物制药公司，开发管理及治疗疼痛和其他中枢神经系统疾病的疗法。Axsome Therapeutics候选产品包含： AXS-02，用于复杂局部疼痛症候群患者治疗疼痛，现处III期临床试验阶段； AXS-05，用于治疗阿兹海默症患者震荡及难治型忧郁症； AXS-02，（对，也是AXS-02，不过不同的开发方向）用于治疗膝骨关节炎及慢性下背疼痛； AXS-06，用于治疗慢性疼痛疾病，处于临床前阶段。Axsome Therapeutics, Inc.个股新闻：2019年1月7日，Axsome Therapeutics股价飙涨+161.60%，源于其AXS-05治疗重度抑郁症的第 II 阶段实验结果。第 II 阶段的研究结果显示，Axsome Therapeutics公司向患有严重抑郁症的患者采用了两种不同剂量的AXS-05，范围从中度到重度。 这包括45mg右美沙芬或105mg活性对照安非他酮，每天两次，持续六周。来自第 ii 阶段试验的好消息是AXS-05能够满足其主要目标：在Montgomery-Åsberg Depression Rating Scale（蒙哥马利抑郁评定量表）上减少了17.2分，相比之下，服用安非他酮的对照患者在相同剂量下减少了12.1分。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-03-28 | Jeffs (Roger A Ph.D.) | Director | Buy | 7344 | 3.67 |
| 2017-03-28 | Jeffs (Roger A Ph.D.) | Director | Buy | 35194 | 4.95 |
| 2015-12-22 | Kaye (Randall E) | Officer | Buy | 1000 | 9.03 |
| 2015-11-23 | Saad (Mark E) | Director | Buy | 3502 | 5.94 |
| 2015-11-23 | Kaye (Randall E) | Officer | Buy | 5022 | 5.40 |
| 2015-11-23 | Jeffs (Roger A Ph.D.) | Director | Buy | 4374 | 5.94 |
| 2015-11-23 | Ames (Constance) | Officer | Buy | 4358 | 5.94 |
| 2015-11-23 | Coleman (Mark H) | Director | Buy | 243750 | 5.40 |
| 2015-11-23 | Coleman (Mark H) | Director | Buy | 140672 | 5.94 |
| 2015-11-23 | Coleman (Mark H) | Director | Buy | 180526 | 5.94 |
| 2015-11-23 | Tabuteau (Herriot M.D.) | Chief Executive Officer | Buy | 7229 | 5.94 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Royce & Associates, LP | 182400 | 0.55% | -150000 | -45.13% | 2019-03-31 |
| RTW INVESTMENTS, LLC | 595635 | 1.79% | 595635 | -- | 2019-03-31 |
| Vanguard Investments Australia Ltd | 657414 | 1.97% | 85669 | 14.98% | 2019-07-31 |
| Millennium Management LLC | 763974 | 2.29% | 455172 | 147.40% | 2019-03-31 |
| BlackRock Fund Advisors | 838536 | 2.52% | 4542 | 0.54% | 2019-07-31 |
| Vanguard Group Inc | 901787 | 2.71% | 563083 | 166.25% | 2019-03-31 |
| VHCP Management III, LLC | 1068044 | 3.21% | 1068044 | -- | 2019-03-31 |
| Alethea Capital Management, LLC | 1140394 | 3.42% | 231965 | 25.53% | 2019-03-31 |
| Baker Bros Advisors LP | 1200000 | 3.60% | 1200000 | -- | 2019-03-31 |
| VHCP Management II, LLC | 571956 | 1.72% | 571956 | -- | 2019-03-31 |
| Invesco Advisers, Inc. | 547975 | 1.65% | 96424 | 21.35% | 2019-07-31 |
| SSGA Funds Management Inc | 211911 | 0.64% | 12960 | 6.51% | 2019-07-31 |
| PURA VIDA INVESTMENTS, LLC | 213645 | 0.64% | 213645 | -- | 2019-03-31 |
| LAURION CAPITAL MANAGEMENT LP | 219000 | 0.66% | 219000 | -- | 2019-03-31 |
| EAM Investors, LLC | 227241 | 0.68% | 227241 | -- | 2019-03-31 |
| Ghost Tree Capital, LLC | 310000 | 0.93% | 310000 | -- | 2019-03-31 |
| Stifel Financial Corp | 404145 | 1.21% | -- | -- | 2019-03-31 |
| AllianceBernstein L.P. | 404488 | 1.21% | 20780 | 5.42% | 2019-07-31 |
| BlackRock Inc | 465587 | 1.40% | 401538 | 626.92% | 2019-03-31 |
| RA Capital Management, LLC | 3293789 | 9.89% | 3293789 | -- | 2019-03-31 |
| Invesco Capital Management LLC | 475375 | 1.43% | -4579 | -0.95% | 2019-06-30 |
| Parallax Volatility Advisers, LLC | 167001 | 0.50% | 167001 | -- | 2019-03-31 |
| Principal Global Investors, LLC | 117273 | 0.35% | -16620 | -12.41% | 2019-05-31 |
| Schonfeld Strategic Advisors LLC | 124500 | 0.37% | 124500 | -- | 2019-03-31 |
| Bridgeway Capital Management, Inc | 128000 | 0.38% | 65000 | 103.17% | 2019-03-31 |
| Fidelity Management & Research Company | 161134 | 0.48% | 4823 | 3.09% | 2019-05-31 |
| Geode Capital Management, LLC | 188410 | 0.57% | 94205 | 100.00% | 2018-12-31 |
| Endurant Capital Management LP | 209195 | 0.63% | 114010 | 119.78% | 2018-12-31 |
| Sio Capital Management, LLC | 380812 | 1.14% | -35646 | -8.56% | 2018-12-31 |
| SEI Investments Management Corp | 113856 | 0.34% | -18796 | -14.17% | 2019-05-31 |
| Oxford Asset Management, LLC | 73713 | 0.22% | 73713 | -- | 2018-12-31 |
| Jacobs Levy Equity Management, Inc. | 74265 | 0.22% | -9900 | -11.76% | 2019-03-31 |
| Dreyfus Corporation | 59540 | 0.18% | -32327 | -35.19% | 2019-04-30 |
| Point72 Asset Management, L.P. | 250000 | 0.75% | 250000 | -- | 2018-12-31 |
| Columbia Mgmt Investment Advisers, LLC | 60864 | 0.18% | -81812 | -57.34% | 2019-03-31 |
| Northern Trust Investments Inc | 44220 | 0.13% | 4686 | 11.85% | 2019-03-31 |
| Mariner Wealth Advisors, LLC | 41525 | 0.12% | -- | -- | 2018-12-31 |
| Spark Investment Management LLC | 40900 | 0.13% | 40900 | -- | 2018-12-31 |
| JPMorgan Chase & Co | 40698 | 0.12% | -40980 | -50.17% | 2018-09-30 |
| Fidelity Management and Research Company | 416252 | 1.27% | -565698 | -57.61% | 2018-09-30 |
| Worth Venture Partners, LLC | 40000 | 0.13% | 40000 | -- | 2018-09-30 |
| J.P. Morgan Securities Inc | 40698 | 0.14% | -40980 | -50.17% | 2018-09-30 |
| Opus Point Partners Management, LLC | 120150 | 0.40% | -13350 | -10.00% | 2018-09-30 |
| FMR Inc | 416252 | 1.40% | -565698 | -57.61% | 2018-09-30 |
| Baldwin Brothers Inc | 30551 | 0.10% | 5000 | 19.57% | 2018-09-30 |
| Fidelity SelectCo, LLC | 375452 | 1.26% | -273163 | -42.11% | 2018-11-30 |
| Allianz Global Investors GmbH | 125670 | 0.42% | -- | -- | 2018-11-30 |
| JPMorgan Asset Management (Europe) S.¨¤ r.l. | 171281 | 0.57% | -791244 | -82.21% | 2018-11-30 |
| Legg Mason Investment Counsel Inc | 404145 | 1.36% | -- | -- | 2018-06-30 |
| Sabby Management LLC | 81159 | 0.27% | 81159 | -- | 2018-03-31 |
| JP Morgan Asset Management (UK) Ltd | 157881 | 0.53% | -1274575 | -88.98% | 2018-03-31 |
| Royce & Associates, LLC | 956000 | 3.74% | 75000 | 8.51% | 2018-03-31 |
| J.P. Morgan Investment Management Inc. | 157881 | 0.62% | -1274575 | -88.98% | 2018-03-30 |
| BlackRock Advisors (UK) Ltd | 35600 | 0.14% | -- | -- | 2018-06-30 |
| Northern Trust Investments N A | 30515 | 0.12% | -- | -- | 2018-06-30 |
| Group One Trading, LP | 39084 | 0.15% | 32386 | 483.52% | 2018-03-31 |
| Vassalluzzo Scott J | 21592 | 0.08% | -37690 | -63.58% | 2018-06-30 |
| Walleye Trading LLC | 28323 | 0.11% | 28323 | -- | 2018-03-31 |
| J P Morgan Asset Management (UK) Ltd | 157881 | 0.62% | -1274575 | -88.98% | 2018-03-31 |
| Dynamic Technology Lab Private Ltd | 26478 | 0.10% | 26478 | -- | 2018-03-31 |
| Forbes J M & Co | 15066 | 0.06% | -- | -- | 2017-12-31 |
| Trexquant Investment LP | 22911 | 0.09% | 22911 | -- | 2017-12-31 |
| Goldman, Sachs & Co. | 42473 | 0.17% | 42473 | -- | 2017-12-31 |
| Susquehanna Financial Group, LLLP | 68795 | 0.27% | 68795 | -- | 2017-12-31 |
| Allianz Global Investors | 125670 | 0.49% | -- | -- | 2017-12-31 |
| Renaissance Technologies Corp | 48400 | 0.19% | 48400 | -- | 2017-12-31 |
| Allianz Global Investors U.S. LLC - San Francisco | 125670 | 0.50% | -- | -- | 2017-12-31 |
| Sphera Funds Management Ltd. | 501000 | 2.12% | -- | -- | 2017-09-30 |
| Squarepoint Ops LLC | 33600 | 0.14% | 33600 | -- | 2017-09-30 |
| Element Capital Management LLC | 61510 | 0.26% | 61510 | -- | 2017-06-30 |
| Sunrise Partners LLC | 48900 | 0.21% | 48900 | -- | 2017-06-30 |
| State Street Corp | 126222 | 0.66% | 12731 | 11.22% | 2016-09-30 |
| BlackRock Advisors LLC | 37940 | 0.20% | -541 | -1.41% | 2016-09-30 |
| TIAA-CREF Investment Management LLC | 32742 | 0.17% | -- | -- | 2016-09-30 |
| California State Teachers Retirement Sys | 23212 | 0.12% | -100 | -0.43% | 2016-09-30 |
| Northern Trust Asset Management | 26413 | 0.14% | 194 | 0.74% | 2016-12-31 |
| Morgan Stanley Smith Barney LLC | 19800 | 0.10% | -39817 | -66.79% | 2016-09-30 |
| BNY Mellon Investment Management | 19385 | 0.10% | -- | -- | 2016-09-30 |
| Charles Schwab Investment Management Inc | 17700 | 0.09% | -- | -- | 2016-09-30 |
| Lombard Odier Asset Management USA Corp | 328061 | 1.71% | -13729 | -4.02% | 2016-09-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| BlackRock Extended Equity Market | 43113 | 0.13% | -59 | -0.14% | 2019-06-30 |
| Invesco DWA SmallCap Momentum ETF | 137897 | 0.41% | -- | -- | 2019-07-31 |
| SPDR | 195746 | 0.59% | 9160 | 4.91% | 2019-07-31 |
| iShares Russell 2000 Growth ETF | 224219 | 0.67% | 3497 | 1.58% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 295454 | 0.89% | -2060 | -0.69% | 2019-06-30 |
| AB Small Cap Growth Portfolio | 344590 | 1.03% | 36250 | 11.76% | 2019-06-30 |
| Invesco Health Care Fund | 477441 | 1.43% | 105185 | 28.26% | 2019-06-30 |
| iShares Russell 2000 ETF | 531357 | 1.60% | 1045 | 0.20% | 2019-07-30 |
| Vanguard Total Stock Market Index Fund | 652039 | 1.96% | 85700 | 15.13% | 2019-06-30 |
| Principal SmallCap Growth Fund I | 123810 | 0.37% | 11650 | 10.39% | 2019-06-30 |
| Royce Low-Priced Stock Fund | 114700 | 0.34% | -67700 | -37.12% | 2019-06-30 |
| Bridgeway Ultra Small Company Market Fd | 114000 | 0.34% | 51000 | 80.95% | 2019-03-31 |
| AB Small Cap Core Portfolio | 43777 | 0.13% | -15470 | -26.11% | 2019-06-30 |
| Russell 2000 Index Non-Lendable Fund E | 48935 | 0.15% | 48935 | -- | 2019-06-30 |
| Schwab Small Cap Index Fund | 50697 | 0.15% | 50697 | -- | 2019-06-30 |
| Vanguard Health Care Index Fund | 60251 | 0.18% | -650 | -1.07% | 2019-06-30 |
| iShares Micro-Cap ETF | 61977 | 0.19% | -- | -- | 2019-07-30 |
| Invesco VI Health Care Fund | 70534 | 0.21% | 14789 | 26.53% | 2019-06-30 |
| Invesco Global Health Care Fund | 91233 | 0.27% | -- | -- | 2019-04-30 |
| Fidelity | 106111 | 0.32% | -- | -- | 2019-06-30 |
| Invesco DWA Healthcare Momentum ETF | 301451 | 0.91% | -- | -- | 2019-06-30 |
| BNY Mellon Select Managers Sm Cp Gr Fd | 37646 | 0.11% | -21373 | -36.21% | 2019-05-31 |
| Vanguard Instl Total Stock Market Idx Fd | 27554 | 0.08% | 4014 | 17.05% | 2019-05-31 |
| SEI Small Cap (SIMT) Fund | 29522 | 0.09% | -23204 | -44.01% | 2019-05-31 |
| Neuberger Berman Small Cap Growth Fund | 20500 | 0.06% | -21500 | -51.19% | 2019-04-30 |
| NT Ext Equity Market Index Fund - L | 18786 | 0.06% | 4348 | 30.11% | 2019-03-31 |
| SEI Small Cap Growth (SIMT) Fund | 26809 | 0.08% | -- | -- | 2019-04-30 |
| SEI Small Cap II (SIIT) Fund | 28631 | 0.09% | -- | -- | 2019-04-30 |
| Dreyfus Select Managers Small Cap Gr Fd | 59540 | 0.18% | -32327 | -35.19% | 2019-03-31 |
| VALIC Company I Small Cap Fund | 14000 | 0.04% | 14000 | -- | 2019-02-28 |
| Multi-Manager Small Cap Equity Strat Fd | 60864 | 0.18% | -81812 | -57.34% | 2019-02-28 |
| SEI Small Cap (SIIT) Fund | 15014 | 0.05% | -10793 | -41.82% | 2019-03-31 |
| NT Extended Equity Market Idx Fund - NL | 13451 | 0.04% | -- | -- | 2019-03-31 |
| SEI Catholic Values Equity Fund (SCVT)Fd | 13322 | 0.04% | -5024 | -27.38% | 2019-03-31 |
| State Street U.S. Extended Market Index | 13100 | 0.04% | -- | -- | 2019-03-31 |
| Vanguard Balanced Index Fund | 10683 | 0.03% | -- | -- | 2019-02-28 |
| iShares Core S&P Total US Stock Mkt ETF | 11278 | 0.03% | 12 | 0.11% | 2019-03-29 |
| Vanguard US Equity Index Fund | 5865 | 0.02% | -- | -- | 2019-01-31 |
| The Vanguard Total Stock Market Index | 4705 | 0.01% | -- | -- | 2019-01-31 |
| 1290 VT Micro Cap Portfolio | 3727 | 0.01% | 546 | 17.16% | 2018-12-31 |
| Invesco Wilshire Micro-Cap ETF | 4579 | 0.01% | -- | -- | 2019-01-31 |
| BNY Mellon Market Completion Fund | 1104 | -- | 1104 | -- | 2018-12-31 |
| Meeder Spectrum Fund | 2533 | 0.01% | -- | -- | 2018-12-31 |
| Invesco All Cap Market Neutral Fund | 23550 | 0.07% | -- | -- | 2018-09-30 |
| Fidelity Advisor | -- | -- | -228263 | -100.00% | 2018-08-31 |
| JPM Global Healthcare Fund | 171281 | 0.57% | -791244 | -82.21% | 2018-03-31 |
| Royce Smaller-Companies Growth Fund | 556000 | 1.86% | -100000 | -15.24% | 2018-06-30 |
| JPM Global Healthcare Fund UL | 171281 | 0.57% | -791244 | -82.21% | 2018-03-31 |
| Allianz Biotechnologie | 125670 | 0.43% | -- | -- | 2017-12-31 |
| Royce Smaller-Companies Growth Svc | 556000 | 2.12% | -100000 | -15.24% | 2018-06-30 |
| Royce Low Priced Stock Svc | 332400 | 1.27% | 32400 | 10.80% | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 197614 | 0.75% | -- | -- | 2018-07-31 |
| Bridgeway Ultra-Small Company Market | 88000 | 0.34% | -- | -- | 2018-06-30 |
| iShares Micro-Cap | 43537 | 0.16% | -- | -- | 2018-09-12 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 34549 | 0.13% | -- | -- | 2018-07-31 |
| Invesco All Cap Market Neutral A | 23550 | 0.09% | 23550 | -- | 2018-06-30 |
| Fidelity Spartan | 21511 | 0.08% | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 331550 | 1.26% | -- | -- | 2018-07-31 |
| Meeder Spectrum | 2029 | 0.01% | 209 | 11.48% | 2018-08-31 |
| AXA/Lord Abbett Micro Cap K | 3181 | 0.01% | -- | -- | 2018-07-31 |
| Wilshire Micro-Cap ETF | 4671 | 0.02% | -- | -- | 2018-09-14 |
| iShares Core S&P Total US Stock Mkt | 9100 | 0.03% | -- | -- | 2018-09-12 |
| Vanguard Balanced Index Inv | 11687 | 0.04% | -- | -- | 2018-07-31 |
| Nuveen Small Cap Index I | 599 | -- | -136 | -18.50% | 2017-03-31 |
| BNY Mellon Market Completion Fund UC1 | 1118 | -- | 1118 | -- | 2017-12-31 |
| Vantagepoint Mid/Small Company Index I | 1967 | 0.01% | -- | -- | 2016-09-30 |
| JPMorgan US Small Company Instl | 138200 | 0.72% | 3400 | 2.52% | 2016-12-31 |
| The Vanguard Russell 2000 Growth Index | 17729 | 0.09% | -- | -- | 2016-12-31 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 26413 | 0.14% | 194 | 0.74% | 2016-12-31 |
| CREF Stock R1 | 28468 | 0.15% | -- | -- | 2016-12-31 |
| iShares Russell 2000 Growth | 87131 | 0.42% | -- | -- | 2017-02-07 |
| Schwab Small Cap Index | 17700 | 0.09% | -- | -- | 2016-12-31 |
| AXA 2000 Managed Volatility K | 13752 | 0.07% | -- | -- | 2016-11-30 |
| BlackRock Russell 2000 | 12851 | 0.07% | 686 | 5.64% | 2016-12-31 |
| BlackRock Russell 2500 | 12366 | 0.06% | 12366 | -- | 2016-12-31 |
| TIAA-CREF Small-Cap Blend Idx Inst | 11659 | 0.06% | -- | -- | 2016-12-31 |
| SST Small Cap 3 | 9300 | 0.05% | -200 | -2.11% | 2016-12-31 |
| Vanguard Russell 2000 ETF | 8108 | 0.04% | 576 | 7.65% | 2016-12-31 |
| LVIP SSgA Small Cap Index Std | 8485 | 0.04% | 8100 | 2103.90% | 2016-12-31 |
| Mark E. Saad | Currently, Mark E. Saad occupies the position of Chief Operating Officer & Partner at Alethea Capital Management LLC. He is also on the board of Axsome Therapeutics, Inc. and Ra Medical Systems, Inc. He previously was Chief Operating Officer for Global Empire LLC, Chief Financial Officer for Bird Rock Bio, Inc., Chief Financial Officer at Cytori Therapeutics, Inc. and Chief Financial Officer of MacroPore Biosurgery, Inc. (a subsidiary of Cytori Therapeutics, Inc.) and Chief Operating Officer-Global Healthcare Group at UBS Investment Bank (US). He received an undergraduate degree from Villanova University. |
|---|---|
| Myrtle S. Potter | Myrtle S. Potter is an entrepreneur and businessperson who founded Myrtle Potter & Co. LLC, Myrtle Potter Media, Inc. and Astra Merck, Inc. and who has been the head of 6 different companies. Presently, she is Chairman for Myovant Sciences Ltd. and Chairman at Urovant Sciences Ltd. Ms. Potter is also Chairman-Vant Operation at Roivant Sciences, Inc. and on the board of 11 other companies. In the past Ms. Potter was Chief Executive Officer of Myrtle Potter & Co. LLC, Chief Executive Officer at Chapman Properties, Inc., Chief Executive Officer of Myrtle Potter Media, Inc., Vice President at Merck & Co., Inc., President-US Cardiovascular & Metabolics at Bristol-Myers Squibb Co. and President & Chief Operating Officer for Genentech, Inc. She received an undergraduate degree from The University of Chicago. |
| Roger A. Jeffs | Roger A. Jeffs founded Bull City Select Investments LLC. He is Co-Owner at this company. Dr. Jeffs is also on the board of 6 other companies. In the past he held the position of President, Co-Chief Executive Officer & Director at United Therapeutics Corp., Associate Director-Clinical Research at Amgen, Inc. and Member-Clinical Research at Glaxo Wellcome, Inc. He received an undergraduate degree from Duke University and a doctorate from UNC School of Medicine. |
| Herriott Tabuteau | Dr. Herriott Tabuteau, MD, is Founder at Antecip Capital Management LLC. Dr. Tabuteau began his professional career as an investment banking analyst at Goldman Sachs and subsequently was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Dr. Tabuteau earned his MD from Yale University School of Medicine and his BA in molecular biology and biochemistry from Wesleyan University. |
| Myrtle S. Potter | Myrtle S. Potter is an entrepreneur and businessperson who founded Myrtle Potter & Co. LLC, Myrtle Potter Media, Inc. and Astra Merck, Inc. and who has been the head of 6 different companies. Presently, she is Chairman for Myovant Sciences Ltd. and Chairman at Urovant Sciences Ltd. Ms. Potter is also Chairman-Vant Operation at Roivant Sciences, Inc. and on the board of 11 other companies. In the past Ms. Potter was Chief Executive Officer of Myrtle Potter & Co. LLC, Chief Executive Officer at Chapman Properties, Inc., Chief Executive Officer of Myrtle Potter Media, Inc., Vice President at Merck & Co., Inc., President-US Cardiovascular & Metabolics at Bristol-Myers Squibb Co. and President & Chief Operating Officer for Genentech, Inc. She received an undergraduate degree from The University of Chicago. |
| Mark L. Jacobson | Mark L. Jacobson occupies the position of Secretary & Senior Vice President-Operations at Axsome Therapeutics, Inc. He previously held the position of Director-Corporate Development at Stemline Therapeutics, Inc. He received an undergraduate degree from Iowa State University and a graduate degree from Columbia University. |
| Mark E. Saad | Currently, Mark E. Saad occupies the position of Chief Operating Officer & Partner at Alethea Capital Management LLC. He is also on the board of Axsome Therapeutics, Inc. and Ra Medical Systems, Inc. He previously was Chief Operating Officer for Global Empire LLC, Chief Financial Officer for Bird Rock Bio, Inc., Chief Financial Officer at Cytori Therapeutics, Inc. and Chief Financial Officer of MacroPore Biosurgery, Inc. (a subsidiary of Cytori Therapeutics, Inc.) and Chief Operating Officer-Global Healthcare Group at UBS Investment Bank (US). He received an undergraduate degree from Villanova University. |
| Cedric O'Gorman | Currently, Cedric O'Gorman is SVP-Clinical Development & Medical Affairs at Axsome Therapeutics, Inc. He previously was Vice President-Medical Affairs for Intra-Cellular Therapies, Inc. He received a doctorate from National University of Ireland and an MBA from The Leonard N Stern School of Business. |
| Mark Coleman | Currently, Mark Coleman is Medical Director at National Spine Center. He is also on the board of Axsome Therapeutics, Inc. and Stimwave Technologies, Inc. and Medical Director-Baltimore Branch at National Spine & Pain Centers Holdings LLC. Mark Coleman received a doctorate from The Johns Hopkins University School of Medicine and an undergraduate degree from Wesleyan University. |
| Mark E. Saad | Currently, Mark E. Saad occupies the position of Chief Operating Officer & Partner at Alethea Capital Management LLC. He is also on the board of Axsome Therapeutics, Inc. and Ra Medical Systems, Inc. He previously was Chief Operating Officer for Global Empire LLC, Chief Financial Officer for Bird Rock Bio, Inc., Chief Financial Officer at Cytori Therapeutics, Inc. and Chief Financial Officer of MacroPore Biosurgery, Inc. (a subsidiary of Cytori Therapeutics, Inc.) and Chief Operating Officer-Global Healthcare Group at UBS Investment Bank (US). He received an undergraduate degree from Villanova University. |
| Nick Pizzie | Presently, Nick Pizzie is CFO & Principal Accounting Officer for Axsome Therapeutics, Inc. He previously occupied the position of Chief Financial Officer & Vice President for Pierre Fabre USA and Senior Finance Director at Immucor, Inc. Mr. Pizzie received an MBA and an undergraduate degree from Rutgers State University of New Jersey. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
Axsome Therapeutics(AXSM.O)盘前涨10.85%，美国食品药品监督管理局称能够在该公司偏头痛药物AXS-07的新药申请目标批准日期之前完成对其生产设施的检查。